Previous 10 | Next 10 |
Gainers: Can-Fite BioPharma (NYSEMKT: CANF ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Del Frisco's Restaurant Group (NASDAQ: DFRG ) +27% . Orion Energy Systems (NASDAQ: OESX ) +23% . Sprint Corporation (NYSE: S ) +22% . ENDRA Life Sciences (NASDAQ: NDRA ) +18% . Sesen...
Aileron Therapeutics (NASDAQ: ALRN ): Q1 GAAP EPS of -$0.49 misses by $0.03. More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Aileron announced a $26 million capital raise via PIPE transaction Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified tumors underway and ahead of schedule ALRN-6924/palbociclib ...
WATERTOWN, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the Company will report financial results for its first quarter ende...
Aileron Therapeutics ( ALRN -1.1% ) announced the closing of its previously announced private placement of Aileron common stock and warrants, resulting in gross proceeds of $26M. More news on: Aileron Therapeutics, Inc., Read more ...
Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal, Partner at Satter Management, joins Aileron’s Board of Directors WATERTOWN, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field o...
Aileron Therapeutics ( ALRN ) has entered into a securities purchase agreement with a group of institutional accredited investors for the private placement of $26M of Aileron common stock and warrants. More news on: Aileron Therapeutics, Inc., Healthcare stocks news, Read more ...
Aileron Therapeutics (NASDAQ: ALRN ): Q4 GAAP EPS of -$0.48 beats by $0.04. More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WATERTOWN, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today that it has entered into a securities purchase agreement with a group o...
Legacy Reserves (NASDAQ: LGCY ) -32% after announcing review of strategic alternatives. More news on: Legacy Reserves Inc., Tailored Brands, Inc., Build-A-Bear Workshop, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN, Texas , July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first...
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...